[go: up one dir, main page]

WO2000062813A3 - Cationic peg-lipids and methods of use - Google Patents

Cationic peg-lipids and methods of use Download PDF

Info

Publication number
WO2000062813A3
WO2000062813A3 PCT/CA2000/000451 CA0000451W WO0062813A3 WO 2000062813 A3 WO2000062813 A3 WO 2000062813A3 CA 0000451 W CA0000451 W CA 0000451W WO 0062813 A3 WO0062813 A3 WO 0062813A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
cationic
lipids
methods
cpls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/000451
Other languages
French (fr)
Other versions
WO2000062813A2 (en
Inventor
Pieter R Cullis
Tao Chen
David B Fenske
Lorne R Palmer
Kim Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to JP2000611949A priority Critical patent/JP5117648B2/en
Priority to CA002370690A priority patent/CA2370690A1/en
Priority to EP00920309A priority patent/EP1173600A2/en
Priority to AU40962/00A priority patent/AU783647B2/en
Publication of WO2000062813A2 publication Critical patent/WO2000062813A2/en
Priority to AU5454801A priority patent/AU5454801A/en
Priority to PCT/CA2001/000555 priority patent/WO2001080900A2/en
Priority to CA002406654A priority patent/CA2406654A1/en
Priority to EP01927519A priority patent/EP1355670A2/en
Priority to US09/839,707 priority patent/US7189705B2/en
Priority to JP2001577996A priority patent/JP2004508012A/en
Priority to AU2001254548A priority patent/AU2001254548B2/en
Publication of WO2000062813A3 publication Critical patent/WO2000062813A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides cationic-polymer-lipid conjugates (CPLs) such as distal cationic-poly(ethylene glycol)-lipid conjugates which can be incorporated into conventional and stealth liposomes or other lipid-based formulation for enhancing cellular uptake. The CPLs of the present invention comprise a lipid moiety; a hydrophilic polymer; and a polycationic moiety. Method of increasing intracellular delivery of nucleic acids are also provided.
PCT/CA2000/000451 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use Ceased WO2000062813A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000611949A JP5117648B2 (en) 1999-04-20 2000-04-20 Cationic PEG lipids and methods of use.
CA002370690A CA2370690A1 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
EP00920309A EP1173600A2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
AU40962/00A AU783647B2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
AU2001254548A AU2001254548B2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
AU5454801A AU5454801A (en) 2000-04-20 2001-04-20 Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
PCT/CA2001/000555 WO2001080900A2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
CA002406654A CA2406654A1 (en) 2000-04-20 2001-04-20 Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
EP01927519A EP1355670A2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers
US09/839,707 US7189705B2 (en) 2000-04-20 2001-04-20 Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
JP2001577996A JP2004508012A (en) 2000-04-20 2001-04-20 Methods for enhancing SPLP-mediated transfection using endosomal membrane destabilizing agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20

Publications (2)

Publication Number Publication Date
WO2000062813A2 WO2000062813A2 (en) 2000-10-26
WO2000062813A3 true WO2000062813A3 (en) 2001-08-09

Family

ID=22443303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000451 Ceased WO2000062813A2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use

Country Status (5)

Country Link
EP (1) EP1173600A2 (en)
JP (2) JP5117648B2 (en)
AU (1) AU783647B2 (en)
CA (1) CA2370690A1 (en)
WO (1) WO2000062813A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9655822B2 (en) 2004-05-25 2017-05-23 Basf Beauty Care Solutions France S.A.S. Hydrated lamellar phases or liposomes which contain a fatty monoamine or a cationic polymer which promotes intracellular penetration, and a cosmetic or pharmaceutical composition containing same, as well as a method of screening such a substance

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
EP1355670A2 (en) * 2000-04-20 2003-10-29 University of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase inhibitor diagnosis and therapy
CN101291653B (en) 2003-07-16 2012-06-27 普洛体维生物治疗公司 lipid-encapsulated interfering RNA
US7803397B2 (en) * 2003-09-15 2010-09-28 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
JP2009507049A (en) * 2005-09-09 2009-02-19 北京徳科瑞医薬科技有限公司 Nanomicelle formulation of vinca alkaloid anticancer drug encapsulated in polyethylene glycol derivative of phospholipid
CN101346393B (en) 2005-11-02 2015-07-22 普洛体维生物治疗公司 Modified siRNA molecules and uses thereof
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
JP5971945B2 (en) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Stimulation of immune responses by enantiomers of cationic lipids
CN111909020A (en) 2008-11-10 2020-11-10 阿布特斯生物制药公司 Lipids and compositions for delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
EP2480668A2 (en) 2009-09-23 2012-08-01 Protiva Biotherapeutics Inc. Compositions and methods for silencing genes expressed in cancer
ES2666559T3 (en) 2009-12-01 2018-05-07 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
BR112013031553A2 (en) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. compositions, mrna encoding a gland and its use, use of at least one mrna molecule and a vehicle for transfer and use of an mrna encoding for exogenous protein
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
RS58077B1 (en) 2012-02-24 2019-02-28 Arbutus Biopharma Corp Trialkyl cationic lipids and methods of use thereof
JP6527331B2 (en) * 2012-03-16 2019-06-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Target-directed amino acid lipid
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
KR20150058139A (en) 2012-06-15 2015-05-28 피디에스 바이오테크놀러지 코퍼레이션 Cationic lipid vaccine compositions and methods of use
WO2014047533A1 (en) 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
WO2014153052A2 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
EP4446413A3 (en) 2013-03-14 2024-12-18 Translate Bio, Inc. Methods for purification of messenger rna
CN105555757A (en) 2013-07-23 2016-05-04 普洛体维生物治疗公司 Compositions and methods for delivering messenger RNA
CN105658242A (en) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 MRNA therapy for phenylketonuria
ES2707966T3 (en) 2013-10-22 2019-04-08 Translate Bio Inc MRNA therapy for the deficiency in argininosuccinate synthesis
CN106164248B (en) 2014-04-25 2019-10-15 川斯勒佰尔公司 Purification of messenger RNA
JP2017536092A (en) 2014-10-02 2017-12-07 プロティバ バイオセラピューティクス インコーポレイテッド Compositions and methods for silencing gene expression of hepatitis B virus
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (en) 2015-07-29 2018-07-31 阿布特斯生物制药公司 Composition for making hepatitis B virus silenced gene expression and method
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7086870B2 (en) 2016-06-30 2022-06-20 アルブータス・バイオファーマー・コーポレイション Compositions and Methods for Delivering Messenger RNA
US20210284733A1 (en) 2016-08-22 2021-09-16 Arbutus Biopharma Corporation Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
MX2019010155A (en) 2017-02-27 2020-12-10 Translate Bio Inc Novel codon-optimized cftr mrna.
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
KR20210060480A (en) 2018-08-24 2021-05-26 트랜슬레이트 바이오 인코포레이티드 Method for purifying messenger RNA
CA3120647A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
US20230039124A1 (en) * 2019-12-20 2023-02-09 Samyang Holdings Corporation Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt
EP4121018A4 (en) 2020-03-17 2024-07-03 Genevant Sciences Gmbh CATIONIC LIPIDS FOR THE DELIVERY OF LIPID NANOPARTICLES OF THERAPEUTIC AGENTS TO HEPATIC STELLAR CELLS
MX2023006056A (en) 2020-11-25 2023-06-06 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids, and related methods of use.
CN118922401A (en) 2022-01-31 2024-11-08 盖纳万科学有限公司 Ionizable cationic lipids for lipid nanoparticles
KR20250031230A (en) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. Lipid nanoparticles for nucleic acid delivery and methods of using the same
WO2024214632A1 (en) * 2023-04-14 2024-10-17 国立大学法人 東京大学 Phosphonium group-containing cationic polymer, and polymer particles and pharmaceutical composition containing same
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025158420A1 (en) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells
WO2025169168A1 (en) 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Extracorporeal transfection of immune effector cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO1998046208A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
WO1999005094A1 (en) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Novel compositions for the delivery of negatively charged molecules
WO1999005303A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
WO1999065461A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Cationic amphiphile micellar complexes
WO2000043043A1 (en) * 1999-01-21 2000-07-27 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831932B1 (en) * 1995-06-07 2004-05-06 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
WO2001064743A1 (en) * 2000-03-02 2001-09-07 Mitsubishi Pharma Corporation GPib-LIPID BOND CONSTRUCT AND USE THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO1998046208A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
WO1999005094A1 (en) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Novel compositions for the delivery of negatively charged molecules
WO1999005303A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
WO1999065461A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Cationic amphiphile micellar complexes
WO2000043043A1 (en) * 1999-01-21 2000-07-27 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANWER K ET AL: "OPTIMIZATION OF CATIONIC LIPID/DNA COMPLEXES FOR SYSTEMIC GENE TRANSFER TO TUMOR LESIONS", JOURNAL OF DRUG TARGETING,HARWOOD ACADEMIC PUBLISHERS GMBH,DE, vol. 8, no. 2, 2000, pages 125 - 135, XP000951678, ISSN: 1061-186X *
ARUNA NATHAN ET AL: "COPOLYMERS OF LYSINE AND POLYETHYLENE GLYCOL: A NEW FAMILY OF FUNCTIONALIZED DRUG CARRIERS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 4, no. 1, 1993, pages 54 - 62, XP000336592, ISSN: 1043-1802 *
BHATTACHARYA S V ET AL: "Synthesis of novel cationic lipids with oxyethylene spacers at the linkages between hydrocarbon chains and pseudoglyceryl backbone", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 46, 12 November 1999 (1999-11-12), pages 8167 - 8171, XP004180445, ISSN: 0040-4039 *
CHEN TAO ET AL: "Fluorescent-labeled poly(ethylene glycol) lipid conjugates with distal cationic headgroups.", BIOCONJUGATE CHEMISTRY, vol. 11, no. 3, May 2000 (2000-05-01), pages 433 - 437, XP002157295, ISSN: 1043-1802, Retrieved from the Internet <URL:http://pubs.acs.org/CHECKCCIP-979559877/isubscribe/journals/bcches/asap/pdf/bc990171x.pdf> [retrieved on 20000330] *
HASELGRUBLER T ET AL: "SYNTHESIS AND APPLICATIONS OF A NEW POLY(ETHYLENE GLYCOL) DERIVATIVE FOR THE CROSSLINKING OF AMINES WITH THIOLS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 6, no. 3, 1 May 1995 (1995-05-01), pages 242 - 248, XP000505483, ISSN: 1043-1802 *
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 *
MACIAN M ET AL: "Preliminary studies of the toxic effects of non-ionic surfactants derived from lysine.", TOXICOLOGY, JAN 8 1996, VOL. 106, NO. 1-3, PAGE(S) 1-9, XP000978704 *
MORI A ET AL: "STABILIZATION AND REGULATED FUSION OF LIPOSOMES CONTAINING A CATIONIC LIPID USING AMPHIPATHIC POLYETHYLENEGLYCOL DERIVATIVES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 8, no. 2, 1 May 1998 (1998-05-01), pages 195 - 211, XP000752693, ISSN: 0898-2104 *
See also references of EP1173600A2 *
TRUBETSKOY V S ET AL: "NEW APPROACHES IN THE CHEMICAL DESIGN OF GD-CONTAINING LIPOSOMES FOR USE IN MAGNETIC RESONANCE IMAGING OF LYMPH NODES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 4, no. 2, 1994, pages 961 - 980, XP000619021, ISSN: 0898-2104 *
TRUBETSKOY V.S. ET AL: "New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes", JOURNAL OF LIPOSOME RESEARCH, 1994, VOL. 4, NO. 2, PAGE(S) 961-983, XP000978705 *
VESKA TONCHEVAL ET AL: "BLOCK COPOLYMERS WITH pH-DEPENDENT SECONDARYSTRUCTURE", JOURNAL OF CONTROLLED RELEASE, vol. 48, no. 2 - 3, October 1997 (1997-10-01), pages 301 - 302, XP002157296, ISSN: 0168-3659 *
WEISSIG V ET AL: "Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool", COLLOIDS AND SURFACES B (BIOINTERFACES), OCT. 2000, ELSEVIER, NETHERLANDS, vol. 18, no. 3-4, pages 293 - 299, XP000971876, ISSN: 0927-7765 *
ZALIPSKY S ET AL: "LONG CIRCULATING, CATIONIC LIPOSOMES CONTAINING AMINO-PEG-PHOSPHATIDYLETHANOLAMINE", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 353, 1994, pages 71 - 74, XP002920144, ISSN: 0014-5793 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655822B2 (en) 2004-05-25 2017-05-23 Basf Beauty Care Solutions France S.A.S. Hydrated lamellar phases or liposomes which contain a fatty monoamine or a cationic polymer which promotes intracellular penetration, and a cosmetic or pharmaceutical composition containing same, as well as a method of screening such a substance
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Also Published As

Publication number Publication date
AU783647B2 (en) 2005-11-17
JP5117648B2 (en) 2013-01-16
JP2002542341A (en) 2002-12-10
JP2012122075A (en) 2012-06-28
EP1173600A2 (en) 2002-01-23
WO2000062813A2 (en) 2000-10-26
CA2370690A1 (en) 2000-10-26
AU4096200A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO2000062813A3 (en) Cationic peg-lipids and methods of use
WO2003068144A3 (en) Cytotoxic agents
FR2840532B1 (en) FURENT LIPID NANOCAPSULES, PROCESS FOR THEIR PREPARATION AND USE AS VECTOR OF ACTIVE (S) PRINCIPLES
WO2000061543A3 (en) Esters of l-carnitine or alkanoyl l-carnitines
WO2000065024A3 (en) Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
WO2001062299A3 (en) Water-soluble polymer conjugates of artelinic acid
WO2001095884A3 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
WO2002034236A3 (en) Lipid formulations for target delivery
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
CA2393638A1 (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
WO1998019709A3 (en) Cationic reagents for transfection
WO2002097116A3 (en) Delivery system for nucleic acids
CA2252055A1 (en) Fusogenic liposomes
EP2471512A3 (en) Non-polar photosensitizer formulations for photodynamic therapy
AU2102101A (en) Use of cationic lipids for intracellular protein delivery
EP1068306A4 (en) Pentaerythritol lipid derivatives
EP2452684A3 (en) Micelles
WO2004105697A3 (en) Novel lipids for transfection of nucleic acids
WO2003102150A3 (en) Multi-functional polyamines for delivery of biologically-active polynucleotides
HK1040486A1 (en) Fatty acid-anticancer conjugates and uses thereof
AU2002362461A1 (en) Targeted therapeutic lipid constructs having cell surface targets
WO2007002886A3 (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2370690

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 2000 611949

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000920309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642